Acurx Q2 Loss Steady at $2.3M; Cash $10.7M, Going Concern Warning Reiterated
ACXP sits 17% above its 52-week low of $1.326 on elevated volume (2.7× avg).
Summary
Acurx Pharmaceuticals posted a Q2 net loss of $2.25 million and reiterated its going concern warning, with $10.7 million in cash insufficient for 12 months. The company raised $6.2 million in H1 2026 through dilutive equity sales.
Key Events · Earnings and Guidance · ACXP
-
Q2 Net Loss Steady
Net loss of $2.25 million for Q2 2026, essentially flat versus $2.25 million in Q2 2025. R&D spending rose 104% to $1.07 million, offset by a 29% drop in G&A to $1.24 million.
-
Going Concern Warning Reiterated
Cash of $10.7 million as of June 30, 2026 will not fund operations for at least 12 months. Management plans to seek additional equity financing and grant funding, but no assurance of availability.
-
Dilutive Financing Continues
Raised $6.2 million in H1 2026: $2.3 million net from an April registered direct offering and $3.9 million net from Lincoln Park ELOC sales. Subsequent ELOC sales added $0.7 million through August 12, 2026.
-
Nasdaq MVLS Rule Disclosed
New Nasdaq rule requiring $5 million minimum Market Value of Listed Securities was approved July 22, 2026, then stayed by the SEC on July 29, 2026 pending review. Company's market cap is near the threshold.
Analysis · ACXP · Life Sciences
Acurx Pharmaceuticals reported a Q2 net loss of $2.25 million, nearly unchanged from a year ago, while reiterating that its $10.7 million cash balance will not fund operations for 12 months. The company continues to rely on dilutive equity sales — $6.2 million raised in H1 2026 via an April registered direct offering and its Lincoln Park equity line — to stay afloat. The going concern warning and ongoing dilution are the core risks for shareholders.
At the time of this filing, ACXP was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $1.33 to $8.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.